Regeneron Pharmaceuticals Eulerpool News

Regeneron Pharmaceuticals Eulerpool News

Regeneron Pharmaceuticals Notizie Azioni

Regeneron Pharmaceuticals è seguito da molti giornalisti e investitori in tutto il mondo. Qui raccogliamo le più recenti notizie Regeneron Pharmaceuticals.

• 11 settembre ·

  Yahoo
  Sanofi, Regeneron's Dupixent Meets Late-Stage Urticaria Study Goals
• 11 settembre ·

  SeekingAlpha
  Fidelity Select Health Care Portfolio Q2 2024 Review
• 11 settembre ·

  Yahoo
  EYLEA HD® (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile
• 11 settembre ·

  Yahoo
  Prediction: These 2 Companies Will Split Their Stocks by 2027
• 11 settembre ·

  Yahoo
  Dupixent succeeds in chronic hives study, giving Sanofi, Regeneron a chance to rebound
• 11 settembre ·

  GlobeNewswire
  EYLEA HD? (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile
• 11 settembre ·

  Seeking Alpha
  Regeneron, Sanofi report mixed outcomes in late-stage trials for Dupixent
• 11 settembre ·

  Alliance News
  Sanofi says test of Dupixent shows 50% improvement in skin condition
• 11 settembre ·

  Yahoo
  Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU)
• 11 settembre ·

  Yahoo
  Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial